DDInter783 DDInter1652
Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Fosphenytoin {u} (Compound) resembles {v} (Compound) Modafinil
Fosphenytoin {u} (Compound) resembles {v} (Compound) Methylphenobarbital
Fosphenytoin {u} (Compound) treats {v} (Disease) epilepsy syndrome
Fosphenytoin {u} (Compound) binds {v} (Gene) CYP2C9
Fosphenytoin {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Central Nervous System Disorganized Electrical Activity
Fosphenytoin {u} (Compound) causes {v} (Side Effect) Encephalopathy
Fosphenytoin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acetylsalicylic acid
Fosphenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Afatinib
Fosphenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Fosphenytoin {u} may lead to a major life threatening interaction when taken with {v} Apremilast
Fosphenytoin (Compound) resembles Modafinil (Compound)
Fosphenytoin (Compound) resembles Methylphenobarbital (Compound)
Fosphenytoin (Compound) treats epilepsy syndrome (Disease)
Fosphenytoin (Compound) binds CYP2C9 (Gene)
Fosphenytoin (Compound) is included by Decreased Central Nervous System Disorganized Electrical Activity (Pharmacologic Class)
Fosphenytoin (Compound) causes Encephalopathy (Side Effect)
Fosphenytoin may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Afatinib
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Fosphenytoin may lead to a major life threatening interaction when taken with Apremilast